Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Marketplace

FDA-cleared respiratory infection assay, 3/18

March 2018—Quidel has received clearance from the FDA to market its Solana respiratory syncytial virus plus human metapneumovirus assay for the detection of nucleic acids isolated from nasal and nasopharyngeal swabs from patients with signs and symptoms of respiratory infection to aid in the diagnosis of RSV and/or hMPV infections.

Biotin interference educational website, 3/18

March 2018—Roche Diagnostics has introduced the biotinfacts.roche.com website to provide laboratorians with up-to-date data on and best practices for biotin interference. The website offers laboratorians information and answers needed to mitigate risk and help ensure patient safety.

CE-IVD mark for PlexPCR VHS test, 2/18

February 2018—SpeeDx announced it has received CE-IVD marking for its PlexPCR VHS multiplex qPCR test. The test offers a single-well solution to cover the detection and differentiation of the main causes of genital and oral lesions—herpes simplex virus types 1 and 2, Treponema pallidum (syphilis), and varicella zoster virus.

Apoptotic cell-free DNA amplification kit, 2/18

February 2018—Sygnis, based in Heidelberg, Germany, announced the launch of its TruePrime Apoptotic Cell-Free DNA Amplification Kit, under its Expedeon brand. The kit enables accurate DNA amplification using cfDNA obtained from plasma, serum, urine, cerebrospinal fluid, and other bodily fluids.

Sterile vacuum filtration system, 2/18

February 2018—MilliporeSigma launched the Stericup Quick Release 500 mL vacuum filtration system, a filter bottle system for sterile filtration of cell culture media, buffers, and reagents.

DNA purification reagents, 2/18

February 2018—Thermo Fisher Scientific released its MagMax DNA Multi-Sample Ultra 2.0 reagents, which provide genetic testing companies, labs, and service providers with high-throughput DNA extraction from blood, saliva, buffy coat, and buccal swabs. The next-generation reagents can purify DNA from 96 samples in 45 minutes on Thermo Scientific KingFisher instruments using a simplified protocol for either small- or large-volume sample input.

Remote mobile microscope, 2/18

February 2018—Spot Imaging introduced its CytoXpress, an FDA-approved consultation method that lets clinicians and technologists transmit a live, interactive image stream directly to the user’s computer, eliminating the travel and wait time associated with on-site consults.

Autofluorescence quenching reagent, 2/18

February 2018—Vector Laboratories introduced the TrueView Autofluorescence Quenching Kit for removing unwanted fluorescence in formalin-fixed, paraffin-embedded tissue samples, blood cells, and structural elements such as collagen and elastin.

Ortho, EKF collaborate on BHB assay, 2/18

February 2018—Ortho Clinical Diagnostics and EKF Diagnostics announced an agreement that allows Ortho customers to access EKF’s Beta-Hydroxybutyrate LiquiColor Assay, a CLIA moderate-complexity test for use on Ortho’s Vitros 4600 Chemistry System and Vitros 5600 Integrated System.

Validate kits for Roche, Abbott analyzers, 2/18

February 2018—LGC Maine Standards announced the release of its Validate SP2 linearity and calibration verification kit. The Validate SP2 kit, in a human serum matrix, evaluates albumin, ceruloplasmin, C-reactive protein, haptoglobin, prealbumin, and rheumatoid factor. Each kit offers five distinct concentrations covering the reportable ranges of Roche Cobas analyzers.